Our next generation pen hardware has shown to deliver a more enjoyable vaping experience and we are confident this new technology also address the high failure rate of other pens on the market.
Coolidge, AZ (PRWEB) November 02, 2016
MüV announced today its newest product lines are now available to licensed Arizona medical cannabis dispensaries. The products will be exclusively manufactured and distributed to dispensaries by Agronomy Innovations, LLC of Coolidge, Arizona.
The MüV Clear Distillate Vape pen line will come in a kit that includes a rechargeable pen, one pre-filled MüV Clear 500mg distillate cannabis oil cartridge and a USB charger. MüV Clear distillate 500mg refill cartridges will also be offered.
MüV’s new Clear Distillate Vape Pen is a potent, solvent free cannabis oil extract that will be greater than 90% THC. The distillate creation and filling of pens will all be done in house in the Agronomy Innovations laboratory under laminar flow hoods to ensure product safety. In addition, rigorous batch testing will be conducted to assure product quality and safety from contaminants.
According to Marketing Director Todd Beckwith, “We are very excited to introduce the MüV Clear distillate pens that offer a number of advantages over current products on the market. Our next generation pen hardware has shown to deliver a more enjoyable vaping experience and we are confident this new technology will also address the high failure rate of other pens on the market. In addition, our unique extraction processes for our distillate delivers one the cleanest and most potent medicines on the market.”
The MüV Clear distillate refill cartridges feature all natural terpenes for taste and will initially come in Tangerine Kush, Pineapple Express, Lemon and Grapefruit flavors.
About MüV - MüV is an affiliate of Agronomy Innovations, LLC and Agronomy Innovations is an affiliate of Alternative Medical Enterprises, LLC. Alternative Medical Enterprises (AME), LLC, is a fully integrated company that brings pharmaceutical industry precision to the development, production and dispensing of medical cannabinoids. AME’s mission is to produce safe, reliable and effective cannabis based therapies with pharmaceutical level quality and consistency.
To the extent any statements made in this press release contain information that is not historical, these statements are forward-looking in nature and merely express our beliefs, expectations or opinions. For example, words such as “may,” “should,” “estimates,” “predicts,” “continues,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “potential,” “strategy” and similar expressions are intended to identify forward-looking statements. Such statements are based on current expectations or estimates and involve a number of known and unknown risks and uncertainties that could cause our actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause or contribute to these differences include, but are not limited to, the following: (i) our ability to implement our business strategy of distributing high quality cannabis products where permissible under applicable law; (ii) availability and cost of additional capital; (iii) our ability to attract, retain and motivate qualified employees and management; (iv) the impact of federal, state or local government regulations; (v) competition in the cannabis industry; (vi) our ability to generate revenues; and (vii) litigation in connection with our business. All forward-looking statements included in this press release and attributable to us or any person acting on our behalf are qualified by this cautionary statement. Forward-looking statements speak only as of the date on which they are made, and, except as required by law, we undertake no obligation to update or revise any forward-looking statement, regardless of whether new information becomes available, future developments occur or otherwise.